A growing array of pharmaceutical options has investigators trying to figure out which drugs and drug combinations are the ...

Morgan Stanley upgraded Vir Biotechnology (NASDAQ:VIR) to Overweight from Equal Weight on Thursday after the cancer drug ...

Linavonkibart is under clinical development by Scholar Rock and currently in Phase I for Prostate Cancer. According to GlobalData, Phase I drugs for Prostate Cancer have a 76% phase transition success ...

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of ...

BNT-325 is under clinical development by BioNTech and currently in Phase II for Castration-Resistant Prostate Cancer (CRPC).

Participation in the 340B Drug Pricing Program does not increase the use of targeted therapy in older patients with advanced prostate cancer, a study suggests.

Francis Medical Inc., a Twin Cities med-tech manufacturer that's developing a way to treat prostrate and other cancers with water vapor, said Tuesday it raised $80 million in its latest equity funding ...

Latham-based medical technology company AngioDynamics is ramping up marketing of its NanoKnife cancer treatment machine after receiving approval from the U.S. Food and Drug Administration for its use ...

New research from the IU School of Medicine found a discovery that could lead to new treatments for prostate cancer. The American Cancer Society said one in eight men will be ...

Gifts in Wills fund one-third of Cancer Research UK’s work. Work that supports life-saving trials for people like Alfred.

The drug is already approved to treat non-metastatic castration-resistant prostate cancer (CRPC), but expansion into hormone-sensitive prostate cancer could unlock a sizeable new market for the drug.

The identification of new drug resistance mechanisms and prostate cancer molecular subtypes based on genomic and proteomic analysis, as well as prognostic and predictive biomarkers, may further ...